Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bexagliflozin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 known ✓ | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 16/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.76 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bexagliflozin SCHEMBL18058586 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL15324561 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL15324563 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL31364363 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL16421564 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL14855909 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL16510222 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL302200 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL22264462 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL17929391 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724042-A1 | METHOD FOR IMPROVING THE INGESTION OF A LIQUID OR VISCOUS SUBSTANCE | Ceva Santé Animale (FR) | 2026-04-15 | — | — | EP | disclosed |
| US-12594243-B2 | Pharmaceutical formulations | THERACOSBIO, LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250241888-A1 | COMPOUND FOR THE MANAGEMENT OF FELINE DIABETES | INCREVET, INC. | 2025-07-31 | — | — | US | disclosed |
| WO-2025056984-A1 | A NOVEL PROCESS FOR THE PREPARATION OF BEXAGLIFLOZIN A SGLT2 INHIBITOR AND ITS INTERMEDIATES THEREOF | VIJAYASRI ORGANICS PRIVATE LIMITED (IN) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025056984-A1 | A NOVEL PROCESS FOR THE PREPARATION OF BEXAGLIFLOZIN A SGLT2 INHIBITOR AND ITS INTERMEDIATES THEREOF | VIJAYASRI ORGANICS PRIVATE LIMITED (IN) | 2025-03-20 | — | — | WO | disclosed |
| US-20240139109-A1 | PHARMACEUTICAL FORMULATIONS | THERACOSBIO LLC (US) | 2024-05-02 | — | — | US | disclosed |
| EP-4225273-A1 | PHARMACEUTICAL FORMULATIONS | Theracosbio, LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116600791-A | Pharmaceutical preparation | 泰拉克斯生物有限责任公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-108239055-B | THR 1442L-aspartic acid eutectic crystal, preparation method and pharmaceutical composition thereof | 杭州领业医药科技有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4206212-A1 | SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Creatron Institute of Pharmaceutical Research Co., Ltd. (CN) | 2023-07-05 | — | — | EP | disclosed |
| US-20220117898-A1 | PHARMACEUTICAL FORMULATIONS | THERACOSBIO, LLC | 2022-04-21 | — | — | US | disclosed |
| WO-2022073151-A1 | PHARMACEUTICAL FORMULATIONS | THERACOS SUB, LLC (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076328-A1 | PHARMACEUTICAL FORMULATIONS | THERACOS SUB, LLC (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594243-B2 | Pharmaceutical formulations | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1744/4885 |
| US-20240139109-A1 | PHARMACEUTICAL FORMULATIONS | SLC5A2, SLC5A1, SLC2A8 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 330/4885 |
| US-20220117898-A1 | PHARMACEUTICAL FORMULATIONS | SLC5A2, SLC5A1, SLC2A8 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 330/4885 |
| US-20250241888-A1 | COMPOUND FOR THE MANAGEMENT OF FELINE DIABETES | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.